Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | ATM | Q13315 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2911537 | 0.98 | ALDH1A1 (0.47) | ALDH1A1POLBSMN1; SMN2HTTTSHR | |
| SCHEMBL17803881 | 0.98 | ALDH1A1 (0.47) | ALDH1A1POLBSMN1; SMN2HTTTSHR | |
| SCHEMBL12987726 | 0.95 | — | — | |
| SCHEMBL12987073 | 0.90 | — | — | |
| SCHEMBL5405289 | 0.82 | ALDH1A1 (0.46) | ALDH1A1POLBSMN1; SMN2HTTTSHR | |
| SCHEMBL12150634 | 0.80 | ALDH1A1 (0.53) | ALDH1A1POLBSMN1; SMN2HTTTSHR | |
| SCHEMBL2914249 | 0.80 | TSHR (0.66) | ALDH1A1POLBSMN1; SMN2HTTTSHR | |
| SCHEMBL4709259 | 0.80 | ALDH1A1 (0.44) | ALDH1A1POLBSMN1; SMN2HTTTSHR | |
| SCHEMBL17093002 | 0.80 | SMN1; SMN2 (0.46) | ALDH1A1POLBSMN1; SMN2HTTTSHR | |
| SCHEMBL25019692 | 0.80 | MAPK1 (0.53) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9359376-B2 | Substituted methylformyl reagents and method of using same to modify physicochemical and/or pharmacokinetic properties of compounds | SPHAERA PHARMA PTE. LTD (SG) | 2016-06-07 | — | — | US | claimed |
| EP-2693876-A1 | SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS | Sphaera Pharma Pte. Ltd (SG) | 2014-02-12 | — | — | EP | claimed |
| WO-2012137225-A1 | SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS | SPHAERA PHARMA PVT. LTD (IN) | 2012-10-11 | — | — | WO | claimed |
| US-9359376-B2 | Substituted methylformyl reagents and method of using same to modify physicochemical and/or pharmacokinetic properties of compounds | SPHAERA PHARMA PTE. LTD (SG) | 2016-06-07 | — | — | US | disclosed |
| US-9359376-B2 | Substituted methylformyl reagents and method of using same to modify physicochemical and/or pharmacokinetic properties of compounds | SPHAERA PHARMA PTE. LTD (SG) | 2016-06-07 | — | — | US | disclosed |
| US-9359376-B2 | Substituted methylformyl reagents and method of using same to modify physicochemical and/or pharmacokinetic properties of compounds | SPHAERA PHARMA PTE. LTD (SG) | 2016-06-07 | — | — | US | disclosed |
| US-20140121367-A1 | SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS | PIVOT HOLDING LLC | 2014-05-01 | — | — | US | disclosed |
| WO-2012137225-A1 | SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS | SPHAERA PHARMA PVT. LTD (IN) | 2012-10-11 | — | — | WO | disclosed |
| EP-1358198-B1 | NOVEL ACYCLIC NUCLEOSIDE PHOSPHONATE DERIVATIVES, SALTS THEREOF AND PROCESS FOR THE PREPARATION OF THE SAME | LG LIFE SCIENCES LTD (KR) | 2010-08-25 | — | — | EP | disclosed |
| US-7723319-B2 | Acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | LG LIFE SCIENCES LTD. (KR) | 2010-05-25 | — | — | US | disclosed |
| CN-1921867-B | Nucleoside phosphonate derivatives for the treatment of HIV infection | LG LIFE SCIENCES LTD | 2010-05-05 | — | — | CN | disclosed |
| US-20060293284-A1 | Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | CHO DONG-GYU | 2006-12-28 | — | — | US | disclosed |
| EP-1715873-A1 | NUCLEOSIDE PHOSPHONATE DERIVATIVES USEFUL IN THE TREATMENT OF HIV INFECTIONS | LG Life Sciences Ltd. (KR) | 2006-11-02 | — | — | EP | disclosed |
| US-20060052346-A1 | Nucleoside phosphonate derivatives useful in the treatment of HIV infections | LG LIFE SCIENCES LTD. (KR) | 2006-03-09 | — | — | US | disclosed |
| WO-2005079812-A1 | NUCLEOSIDE PHOSPHONATE DERIVATIVES USEFUL IN THE TREATMENT OF HIV INFECTIONS | LG LIFE SCIENCES LTD. (KR) | 2005-09-01 | — | — | WO | disclosed |
| CN-1487949-A | Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | ��ʽ����LG������ѧ | 2004-04-07 | — | — | CN | disclosed |
| US-20040063668-A1 | Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | LG LIFE SCIENCES LTD. (KR) | 2004-04-01 | — | — | US | disclosed |
| EP-1358198-A1 | NOVEL ACYCLIC NUCLEOSIDE PHOSPHONATE DERIVATIVES, SALTS THEREOF AND PROCESS FOR THE PREPARATION OF THE SAME | LG Chem Investment, Ltd. (KR) | 2003-11-05 | — | — | EP | disclosed |
| WO-2002057288-A1 | NOVEL ACYCLIC NUCLEOSIDE PHOSPHONATE DERIVATIVES, SALTS THEREOF AND PROCESS FOR THE PREPARATION OF THE SAME | LG LIFE SCIENCES LTD. (KR) | 2002-07-25 | — | — | WO | disclosed |
| US-4599329-A | O,S-dialkyl S-[carbamyloxyalkyl] dithiophosphates and their use as pesticides | BASF AKTIENGESELLSCHAFT (DE) | 1986-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052346-A1 | Nucleoside phosphonate derivatives useful in the treatment of HIV infections | PNP, TYMP, ENTPD5 | ALDH1A1 1512/4885POLB 149/4885SMN1; SMN2 3295/4885 |
| US-20140121367-A1 | SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS | TPMT, BHMT2, PFAS | ALDH1A1 524/4885POLB 2326/4885SMN1; SMN2 2629/4885 |
| US-20060293284-A1 | Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | PNP, ITPA, MTAP | ALDH1A1 2937/4885POLB 189/4885SMN1; SMN2 3377/4885 |
| US-20040063668-A1 | Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | PNP, ITPA, MTAP | ALDH1A1 2937/4885POLB 189/4885SMN1; SMN2 3377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.